On April 25, 2017, I posted a blog asking the question, Who Is The Biopharmaceutical CEO Of The Year. In the blog, I included a link to a short survey. Our goal was twofold: see if there was enough interest in continuing to pursue such an award, and generate an initial list of names that would be in contention. Thus far, 10 names have been submitted via dozens of submissions, but it’s too early for us to make any decisions or conclusions based on such a small amount of data.
Alan Dunton, M.D., joined Purdue Pharma as the SVP of R&D back in November 2015. An executive with over 33 years of discovery and development experience, he has been responsible for the approval of more than 20 prescription and OTC products. But now he faces a new challenge. Purdue Pharma is a company whose name has become synonymous with pain management.
In 2012, Pfizer announced a big decision — It was spinning off its $4 billion animal health business. Life Science Leader will explore the difficult task of such an undertaking in our June 2017 issue. And while the article, How Pfizer And Zoetis Launched One Of The Most Successful Spinoffs — Ever, discusses a lot of the important business decisions that were made, one thing not covered in great detail was the opportunity for Zoetis to build a corporate culture of its own.
In March I attended The Conference Forum’s R&D Leadership Summit. One of the panels that provided a great deal of insight involved executives discussing how to assess and create value for patients, payors, regulators, and society. This event employs the Chatham House Rule, which means “Neither the identity nor the affiliation of the speaker(s), nor that of any other participant, may be revealed.” Despite not being able to reveal that info, I still think the ideas that were shared will prove valuable.
Recognized today as one of the world’s most-innovative companies, BioMarin was a far cry from that 12 years ago when Jean-Jacques Bienaimé took over.
If you have never served on a corporate board, you might be curious as to what it all entails. Thanks to BioBreak and Drexel University, Life Science Leader undertook the development of a three-part series of articles titled “Journey To The Corporate Boardroom.”
Having Jean-Jacques (J.J.) Bienaimé, chairman and CEO of BioMarin Pharmaceutical, on our cover this month represents a recent trend happening at our magazine — we’re interviewing more and more CEOs and presidents.
In the July 2017, Life Science Leader magazine we will be publishing the article — Balancing Biopharma’s Bright Future Against Its Tarnished Image — 6 Retired CEOs Share Insights For Today’s Industry Leaders. The story features six former CEOs: Mike Bonney (Cubist); Hank McKinnell, Ph.D., (Pfizer); Francois Nader, M.D., (NPS Pharmaceuticals); David Pyott (Allergan); Stephen Sherwin, M.D., (Cell Genesys); and Henri Termeer (Genzyme).
With the BIO International 2017 Convention being just seven weeks away, your preparations as an attendee should be well underway. But until they arrive on-site, many people often overlook deciding what educational sessions to attend. And while BIO attendees can afford to take such an approach, speakers certainly cannot. As the past BIO educational planning co-chair, I can attest that a lot of work goes into pulling off a high-quality educational session at BIO. Consider the following example.